Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate.

Journal: Rheumatology and therapy
Published Date: Dec 11, 2015

Abstract

INTRODUCTION: Early prognostic factors for the clinical response in patients with rheumatoid arthritis (RA) after 1 year of treatment with infliximab (IFX) as part of routine clinical practice were investigated.

Authors

  • Satoko Hayashi
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Katsuya Suzuki
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Keiko Yoshimoto
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Masaru Takeshita
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Takahiko Kurasawa
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kunihiro Yamaoka
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. tsutake@z5.keio.jp.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals